Discussion posted on Pharmaceutical Discussion Group on Linkedin
PhRMA says price as trigger for compulsory license is not provided for in TRIPS - wonder if TRIPS provides for 3200% premium for innovation?
Reference article:
PhRMA’s Special 301 comments to the U.S. Trade Representative include a section on the compulsory licensing provisions in India’s Patents Act. PhRMA recommends that “India should ensure that the CL provisions comply with TRIPS...